Sterilized and Still Infectious

Reusable duodenoscopes and other complex endoscopes cannot be reliably sterilized between patients using current reprocessing methods. The instruments' intricate internal channels and elevator mechanisms trap biological material that resists cleaning and high-level disinfection, resulting in persistent contamination rates of 4-6% even when manufacturer instructions are followed exactly. This has caused multi-drug-resistant organism (MDRO) outbreaks — particularly carbapenem-resistant Enterobacteriaceae (CRE) — at hospitals across the United States. FDA human factors studies show that many steps in reprocessing instructions cannot be reliably performed by healthcare facility staff, making this a fundamental design deficiency rather than a compliance failure.

Approximately 500,000-700,000 ERCP (endoscopic retrograde cholangiopancreatography) procedures are performed annually in the United States, each requiring a duodenoscope. MDRO transmission from contaminated endoscopes can cause sepsis, prolonged hospitalization, and death — CRE infections carry mortality rates of 40-50% in vulnerable patient populations. The economic cost of a single hospital-associated CRE outbreak can exceed $10 million in treatment, litigation, and operational disruption. Between January 2013 and December 2014 alone, the FDA received 75 adverse event reports involving approximately 135 patients, and outbreaks have continued at hospitals worldwide.

The FDA recommended in 2022 that healthcare facilities transition from fixed-endcap duodenoscopes to disposable-endcap or fully disposable designs. Pentax Medical received FDA clearance in 2024 for the first duodenoscope compatible with hydrogen peroxide gas plasma sterilization (STERRAD). However, fully disposable duodenoscopes cost significantly more per procedure than reprocessed reusable devices, creating economic barriers to adoption. Disposable designs may not yet match the mechanical performance — angulation precision and elevator control — of reusable instruments for complex ERCP cases. Most facilities worldwide continue to use reusable instruments. The core engineering failure is that duodenoscopes require a complex mechanical elevator at the distal tip for ERCP procedures, and this mechanism creates internal recesses that cannot be adequately cleaned or visually inspected. No point-of-use test exists that can confirm successful decontamination of a reprocessed endoscope before its next use.

A rapid, reliable point-of-use sterility verification test for endoscopes would immediately improve safety by catching reprocessing failures before the device is used on another patient. A redesigned elevator mechanism that eliminates internal recesses — maintaining ERCP functionality while enabling complete visual inspection and cleaning access — would address the root design deficiency. Significant cost reduction in disposable duodenoscope manufacturing could accelerate the transition away from reusable instruments by closing the per-procedure cost gap.

A student team could develop a rapid biocontamination detection system for endoscope channels — for example, an ATP bioluminescence probe or fluorescence-based sensor designed to fit through the instrument's working channel and detect residual biological material in real time. Another entry point would be designing and prototyping an alternative elevator mechanism geometry that maintains the range of motion needed for ERCP while eliminating the internal recesses that trap contaminants. Teams with backgrounds in mechanical engineering, biomedical device design, microbiology, or optical sensing would be well-suited. A scoped semester project could focus on benchtop testing with surrogate contamination rather than clinical validation.